Even when there is initial therapeutic sensitivity to a conventional chemotherapy or targeted therapy, tumors can become resistant and recur. Methods that model and predict therapeutic resistance of cancer can be extremely useful in the development of more effective treatments for cancer. Our long-term goal is to develop strategies to model, predict, and target therapeutic resistance of cancer. Our proposed approach is to utilize conditional transgenic mouse models combined with computational modeling. We hypothesize that therapeutic resistance to oncogene inactivation can be modeled and thus predicted as a consequence of clonal evolution of tumor cells driven by both cell autonomous and immune-mediated selective pressures. Our approach in Aim 1 is to build a mathematical model that incorporates the roles of the immune system and of evolutionary dynamics to predict the emergence of therapeutic resistance upon oncogene inactivation. Then, in Aim 2 we will experimentally interrogate the roles of the immune system and of evolutionary dynamics in the emergence of therapeutic resistance. We will directly examine immune effectors/cytokines and clonal evolution in our conditional transgenic mouse model with intravital microscopy and bioluminescence imaging. Finally, in Aim 3 we will validate in vivo our mathematical model's predictions of the emergence of therapeutic resistance under novel circumstances.
Even when there is initial therapeutic sensitivity to a conventional chemotherapy or targeted therapy, tumors can become resistant and recur. Our recent results have demonstrated unexpected ways in which the immune system has a critical role in determining the response to shutting down the oncogene driving the cancer. We propose to model, predict and target therapeutic resistance in cancer using transgenic mouse models and mathematical modeling together so that more effective anti-cancer therapies can be developed.
|Gouw, Arvin M; Eberlin, Livia S; Margulis, Katherine et al. (2017) Oncogene KRAS activates fatty acid synthase, resulting in specific ERK and lipid signatures associated with lung adenocarcinoma. Proc Natl Acad Sci U S A 114:4300-4305|
|Mayer, Aaron T; Natarajan, Arutselvan; Gordon, Sydney R et al. (2017) Practical Immuno-PET Radiotracer Design Considerations for Human Immune Checkpoint Imaging. J Nucl Med 58:538-546|
|Beinat, Corinne; Alam, Israt S; James, Michelle L et al. (2017) Development of [18F]DASA-23 for Imaging Tumor Glycolysis Through Noninvasive Measurement of Pyruvate Kinase M2. Mol Imaging Biol 19:665-672|
|Natarajan, Arutselvan; Mayer, Aaron T; Reeves, Robert E et al. (2017) Development of Novel ImmunoPET Tracers to Image Human PD-1 Checkpoint Expression on Tumor-Infiltrating Lymphocytes in a Humanized Mouse Model. Mol Imaging Biol 19:903-914|
|Casey, Stephanie C; Baylot, Virginie; Felsher, Dean W (2017) MYC: Master Regulator of Immune Privilege. Trends Immunol 38:298-305|
|Ronald, John A; Kim, Byung-Su; Gowrishankar, Gayatri et al. (2017) A PET Imaging Strategy to Visualize Activated T Cells in Acute Graft-versus-Host Disease Elicited by Allogenic Hematopoietic Cell Transplant. Cancer Res 77:2893-2902|
|Hori, Sharon Seiko; Lutz, Amelie M; Paulmurugan, Ramasamy et al. (2017) A Model-Based Personalized Cancer Screening Strategy for Detecting Early-Stage Tumors Using Blood-Borne Biomarkers. Cancer Res 77:2570-2584|
|Gouw, Arvin M; Toal, Georgia G; Felsher, Dean W (2016) Metabolic vulnerabilities of MYC-induced cancer. Oncotarget 7:29879-80|
|Felsher, Dean W; Lowe, Leroy (2016) Affordable Cancer Medications Are Within Reach but We Need a Different Approach. J Clin Oncol 34:2194-5|
|Casey, Stephanie C; Tong, Ling; Li, Yulin et al. (2016) MYC regulates the antitumor immune response through CD47 and PD-L1. Science 352:227-31|
Showing the most recent 10 out of 27 publications